Intranasal Delivery of Influenza Subunit Vaccine Formulated with GEM Particles As an Adjuvant

Overview

Journal AAPS J

Specialty Pharmacology

Date 2010 Jan 9

PMID 20058113

Citations 28

Authors

Vinay Saluja

Jean P Amorij

Maarten L van Roosmalen

Kees Leenhouts

Anke Huckriede

Wouter L J Hinrichs

Henderik W Frijlink

Affiliations

Soon will be listed here.

Abstract

Nasal administration of influenza vaccine has the potential to facilitate influenza control and prevention. However, when administered intranasally (i.n.), commercially available inactivated vaccines only generate systemic and mucosal immune responses if strong adjuvants are used, which are often associated with safety problems. We describe the successful use of a safe adjuvant Gram-positive enhancer matrix (GEM) particles derived from the food-grade bacterium Lactococcus lactis for i.n. vaccination with subunit influenza vaccine in mice. It is shown that simple admixing of the vaccine with the GEM particles results in a strongly enhanced immune response. Already after one booster, the i.n. delivered GEM subunit vaccine resulted in hemagglutination inhibition titers in serum at a level equal to the conventional intramuscular (i.m.) route. Moreover, i.n. immunization with GEM subunit vaccine elicited superior mucosal and Th1 skewed immune responses compared to those induced by i.m. and i.n. administered subunit vaccine alone. In conclusion, GEM particles act as a potent adjuvant for i.n. influenza immunization.

Citing Articles

A gram-positive enhancer matrix particles vaccine displaying swine influenza virus hemagglutinin protects mice against lethal H1N1 viral challenge.

Zhang Y, Zhang P, Du X, Shi X, Wang J, Liu S Front Immunol. 2025; 15():1432989.

PMID: 39835123 PMC: 11743504. DOI: 10.3389/fimmu.2024.1432989.

Oral Immunisation With Non-GMO Surface Displayed SARS-CoV-2 Spike Epitopes on Bacteria-Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice.

Vasquez R, Song J, Mendoza R, Hwang I, Bagon B, Engstrand L Microb Biotechnol. 2025; 18(1):e70073.

PMID: 39797809 PMC: 11724470. DOI: 10.1111/1751-7915.70073.

The Mechanisms and Application Value of Postbiotics in Caries Prevention and Management.

Jiang X, Lin M, Xiao P, Zhou Z, Zhang Y, Yan W Oral Health Prev Dent. 2024; 22:465-478.

PMID: 39264370 PMC: 11619881. DOI: 10.3290/j.ohpd.b5740317.

A novel bacterium-like particles platform displaying antigens by new anchoring proteins induces efficacious immune responses.

Niu L, Gao M, Ren H, De X, Jiang Z, Zhou X Front Microbiol. 2024; 15:1395837.

PMID: 38841059 PMC: 11150769. DOI: 10.3389/fmicb.2024.1395837.

Bacterium-like particles derived from probiotics: progress, challenges and prospects.

Zhou X, Gao M, De X, Sun T, Bai Z, Luo J Front Immunol. 2023; 14:1263586.

PMID: 37868963 PMC: 10587609. DOI: 10.3389/fimmu.2023.1263586.

References

Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V . Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine. 2008; 26(51):6555-63. DOI: 10.1016/j.vaccine.2008.09.057. View

Hu K, Lovgren-Bengtsson K, Morein B . Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev. 2001; 51(1-3):149-59. DOI: 10.1016/s0169-409x(01)00165-x. View

Hovden A, Cox R, Haaheim L . Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand J Immunol. 2005; 62(1):36-44. DOI: 10.1111/j.1365-3083.2005.01633.x. View

Cox R, Haaheim L, Ericsson J, Madhun A, Brokstad K . The humoral and cellular responses induced locally and systemically after parenteral influenza vaccination in man. Vaccine. 2006; 24(44-46):6577-80. DOI: 10.1016/j.vaccine.2006.05.041. View

Giudice E, Campbell J . Needle-free vaccine delivery. Adv Drug Deliv Rev. 2006; 58(1):68-89. DOI: 10.1016/j.addr.2005.12.003. View

Amorij J, Westra T, Hinrichs W, Huckriede A, Frijlink H . Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model. Vaccine. 2007; 26(1):67-76. DOI: 10.1016/j.vaccine.2007.10.045. View

Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z . Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine. 2004; 22(20):2566-77. DOI: 10.1016/j.vaccine.2003.12.018. View

Hagenaars N, Mastrobattista E, Verheul R, Mooren I, Glansbeek H, Heldens J . Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. Pharm Res. 2009; 26(6):1353-64. DOI: 10.1007/s11095-009-9845-y. View

Zee Y, OSEBOLD J, Dotson W . Antibody responses and interferon titers in the respiratory tracts of mice after aerosolized exposure to influenza virus. Infect Immun. 1979; 25(1):202-7. PMC: 414438. DOI: 10.1128/iai.25.1.202-207.1979. View

10.

Bienenstock J, McDermott M . Bronchus- and nasal-associated lymphoid tissues. Immunol Rev. 2005; 206:22-31. DOI: 10.1111/j.0105-2896.2005.00299.x. View

11.

Bosma T, Kanninga R, Neef J, Audouy S, van Roosmalen M, Steen A . Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol. 2006; 72(1):880-9. PMC: 1352190. DOI: 10.1128/AEM.72.1.880-889.2006. View

12.

Tamura S, Kurata T . Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis. 2004; 57(6):236-47. View

13.

Tamura S, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T . Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol. 1992; 22(2):477-81. DOI: 10.1002/eji.1830220228. View

14.

Rimmelzwaan G, Fouchier R, Osterhaus A . Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol. 2007; 18(6):529-36. DOI: 10.1016/j.copbio.2007.11.002. View

15.

Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D . A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine. 2006; 24(18):3990-4006. DOI: 10.1016/j.vaccine.2005.12.017. View

16.

Fujihashi K, Koga T, van Ginkel F, Hagiwara Y, McGhee J . A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine. 2002; 20(19-20):2431-8. DOI: 10.1016/s0264-410x(02)00155-x. View

17.

Eyles J, Williamson E, Alpar H . Intranasal administration of influenza vaccines: current status. BioDrugs. 2007; 13(1):35-59. DOI: 10.2165/00063030-200013010-00005. View

18.

Matassov D, Cupo A, Galarza J . A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 2007; 20(3):441-52. DOI: 10.1089/vim.2007.0027. View

19.

Audouy S, van Roosmalen M, Neef J, Kanninga R, Post E, van Deemter M . Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine. 2006; 24(26):5434-41. DOI: 10.1016/j.vaccine.2006.03.054. View

20.

Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A . Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir Viruses. 2009; 2(2):41-51. PMC: 4941893. DOI: 10.1111/j.1750-2659.2008.00038.x. View